Ling Ma
Impact in
-
- Cancer-related Molecular Pathways
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Reproductive Medicine top 10%
- Ovarian cancer diagnosis and treatment
Papers in
- Oncology 11
- PARP inhibition in cancer therapy 4
- Cancer Treatment and Pharmacology 3
-
- Advanced Breast Cancer Therapies 4
- Co-authors
- Kristian Berg (1 shared paper)Živilė Lukšiené (1 shared paper)Johan Moan (1 shared paper)Michael Danso (5 shared papers)Sharon Wilks (5 shared papers)Željko Vojnović (4 shared papers)Antoinette R. Tan (4 shared papers)Lazar Popović (4 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)Cancer (1 paper)Clinical Cancer Research (1 paper)Journal of Materials Chemistry B (1 paper)Medicine (1 paper)
- Partner nations
- United StatesCroatiaSerbia
In The Last Decade
Ling Ma
16 papers receiving 381 citations
Peers
Comparison fields: 5 of 61
- Oncology 176
- Reproductive Medicine 48
- Pulmonary and Respiratory Medicine 177
- Cancer Research 52
- Obstetrics and Gynecology 25
Countries citing papers authored by Ling Ma
This map shows the geographic impact of Ling Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Ma more than expected).
Fields of papers citing papers by Ling Ma
This network shows the impact of papers produced by Ling Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Ma. The network helps show where Ling Ma may publish in the future.
Co-authors
The 25 scholars most cited alongside Ling Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 86 | |
| 2 | 2016 | 64 | |
| 3 | 1995 | 47 | |
| 4 | 2019 | 33 | |
| 5 | 2021 | 28 | |
| 6 | 2021 | 25 | |
| 7 | 2016 | 21 | |
| 8 | 2022 | 17 | |
| 9 | 2020 | 14 | |
| 10 | 2016 | 13 | |
| 11 | 2014 | 12 | |
| 12 | 2022 | 10 | |
| 13 | 2021 | 6 | |
| 14 | 2021 | 5 | |
| 15 | 2023 | 4 | |
| 16 | 2021 | 3 | |
| 17 | 2019 | 0 |
About Ling Ma
Ling Ma is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Reproductive Medicine and Cancer Research, having authored 17 papers that have together received 388 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (4 papers), Advanced Breast Cancer Therapies (4 papers), Cancer Treatment and Pharmacology (3 papers), Ovarian cancer diagnosis and treatment (3 papers), Breast Cancer Treatment Studies (2 papers), Nanoplatforms for cancer theranostics (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Endometrial and Cervical Cancer Treatments (2 papers). The work is most often cited by research in Oncology (176 citations), Reproductive Medicine (48 citations), Pulmonary and Respiratory Medicine (177 citations), Cancer Research (52 citations) and Obstetrics and Gynecology (25 citations). Ling Ma has collaborated with scholars based in United States, Croatia and Serbia. Frequent co-authors include Kristian Berg, Živilė Lukšiené, Johan Moan, Michael Danso, Sharon Wilks, Željko Vojnović, Antoinette R. Tan, Lazar Popović, Gail S. Wright and Donald Richards. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Clinical Cancer Research, Journal of Materials Chemistry B and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.